Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries.
Morrocchi E, Pascucci GR, Cotugno N, Pighi C, Dominguez-Rodriguez S, Petrara MR, Tagarro A, Kuhn L, Cotton MF, Otwombe K, Lain MG, Vaz P, Barnabas SL, Spyer MJ, Lopez E, Fernández-Luis S, Nhampossa T, Maiga AI, Dolo O, De Rossi A, Rojo P, Giaquinto C, Lichterfeld M, Violari A, Smit T, Behuhuma O, Klein N, De Armas L, Pahwa S, Rossi P, Palma P; EPIICAL consortium. Morrocchi E, et al. Sci Rep. 2024 Oct 28;14(1):25792. doi: 10.1038/s41598-024-74066-4. Sci Rep. 2024. PMID: 39468166 Free PMC article.
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium.
Kuhn L, Barnabas S, Cotugno N, Peay H, Goulder P, Cotton M, Violari A, Pahwa S, Reddy K, Tagarro A, Otwombe K, Fry S, Vaz P, Lain MG, Nhampossa T, Archary M, Maiga AI, Puthanakit T, Kityo CM, Foster C, Rojo P, Klein N, Nastouli E, Tiemessen CT, de Rossi A, Ndung'u T, Persaud D, Lichterfeld M, Giaquinto C, Palma P, Rossi P; EPIICAL consortium. Kuhn L, et al. Among authors: kityo cm. Lancet HIV. 2024 Oct;11(10):e700-e710. doi: 10.1016/S2352-3018(24)00157-7. Epub 2024 Jul 23. Lancet HIV. 2024. PMID: 39059402 Review.
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28. Lancet Infect Dis. 2024. PMID: 38821073 Clinical Trial.
Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study.
Jensen TO, Murray TA, Grandits GA, Jain MK, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens R, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Jensen TO, et al. Lancet Microbe. 2024 Jun;5(6):e559-e569. doi: 10.1016/S2666-5247(24)00015-6. Epub 2024 May 27. Lancet Microbe. 2024. PMID: 38815595 Free article. Clinical Trial.
Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries.
Shah NS, Kityo C, Hughes MD, McCarthy C, Wallis C, Hosseinipour M, Langat D, Nyirenda M, Rassool M, Dawson R, Joseph Y, Some F, Mngqbisa R, Mukwekwerere PG, Woolley E, Godfrey C, Manabe YC, Mellors JW, Flexner C, Maartens G; ACTG A5381/Hakim Study Team. Shah NS, et al. Among authors: kityo c. Clin Infect Dis. 2024 May 13:ciae269. doi: 10.1093/cid/ciae269. Online ahead of print. Clin Infect Dis. 2024. PMID: 38739755
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.
Turkova A, Chan MK, Kityo C, Kekitiinwa AR, Musoke P, Violari A, Variava E, Archary M, Cressey TR, Chalermpantmetagul S, Sawasdichai K, Ounchanum P, Kanjanavanit S, Srirojana S, Srirompotong U, Welch S, Bamford A, Epalza C, Fortuny C, Colbers A, Nastouli E, Walker S, Carr D, Conway M, Spyer MJ, Parkar N, White I, Nardone A, Thomason MJ, Ferrand RA, Giaquinto C, Ford D; D3 trial team. Turkova A, et al. Among authors: kityo c. Contemp Clin Trials. 2024 Jul;142:107540. doi: 10.1016/j.cct.2024.107540. Epub 2024 Apr 16. Contemp Clin Trials. 2024. PMID: 38636725 Free article. Clinical Trial.
255 results